ArticleCancer research and treatment2017
Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
Open access · diamondAbstract readMulticenter Study
In one paragraph
Article in Cancer research and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 3 pooled it
1.2field-weighted citation impact, top 20% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.The Cochrane database of systematic reviews · 2021Pooled it
- A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma.Frontiers in oncology · 2021Pooled it
- Prognostic Value and Risk Factors of Treatment-Related Lymphopenia in Malignant Glioma Patients Treated With Chemoradiotherapy: A Systematic Review and Meta-Analysis.Frontiers in neurology · 2021Pooled it
- Efficacy and safety of carmustine wafers, followed by radiation, temozolomide, and bevacizumab therapy, for newly diagnosed glioblastoma with maximal resection.International journal of clinical oncology · 2025Trial
- Levetiracetam as a sensitizer of concurrent chemoradiotherapy in newly diagnosed glioblastoma: An open-label phase 2 study.Cancer medicine · 2022Trial
- Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.Journal of neuro-oncology · 2020Trial
- Development of Surfactant-Modified Liposomal Lomustine to Improve Blood-Brain Barrier Transport and Therapeutic Outcomes in Glioblastoma.ACS omega · 2026Article
- Iron Mediates Radiation-Induced Glioblastoma Cell Diffusion.International journal of molecular sciences · 2025Article
- NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors.Acta neuropathologica communications · 2024Article
- Glioma angiogenesis is boosted by ELK3 activating the HIF-1BMC cancer · 2023Article
- Lymphoproliferative disorder during temozolomide therapy; a representative case of a formidable complication and management challenges.BMC neurology · 2023Article
- The Korean Society for Neuro-Oncology (KSNO) Guideline for the Management of Brain Tumor Patients During the Crisis Period: A Consensus Recommendation Using the Delphi Method (Version 2023.1).Brain tumor research and treatment · 2023Article
- Effect of Choline Alphoscerate on the Survival of Glioblastoma Patients: A Retrospective, Single-Center Study.Journal of clinical medicine · 2022Article
- Relapsing High-Grade Glioma from Peritumoral Zone: Critical Review of Radiotherapy Treatment Options.Brain sciences · 2022Review
- PrACTiC: A Predictive Algorithm for Chemoradiotherapy-Induced Cytopenia in Glioblastoma Patients.Journal of oncology · 2022Article
- Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study.CNS oncology · 2021Article
- Mixed malignant glioblastoma and schwannoma in spinal cord with metachronous ependymoma: A case report.Clinical case reports · 2021Article
- Evaluating survival in subjects with astrocytic brain tumors by dynamic susceptibility-weighted perfusion MR imaging.PloS one · 2021Article
- Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres.Journal of cancer research and clinical oncology · 2020Article
- Clinical Characteristics of High-Grade Glioma with Primary Leptomeningeal Seeding at Initial Diagnosis in a Single Center Study.Brain tumor research and treatment · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors at 20 institutions in 1 country.
Byung Sup KimDepartment of Neurosurgery, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea.
Ho Jun SeolDepartment of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Do-Hyun NamDepartment of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Chul-Kee ParkDepartment of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Il Han KimDepartment of Radiation Oncology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Tae Min KimDivision of Hematology/Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Jeong Hoon KimDepartment of Neurosurgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Young Hyun ChoDepartment of Neurosurgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Sang Min YoonDepartment of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jong Hee ChangDepartment of Neurosurgery, Brain Tumor Center, Yonsei University Health System, Seoul, Korea.
Seok-Gu KangDepartment of Neurosurgery, Brain Tumor Center, Yonsei University Health System, Seoul, Korea.
Eui Hyun KimDepartment of Neurosurgery, Brain Tumor Center, Yonsei University Health System, Seoul, Korea.
Chang-Ok SuhDepartment of Radiation Oncology, Brain Tumor Center, Yonsei University Health System, Seoul, Korea.
Tae-Young JungDepartment of Neurosurgery, Chonnam National University Hwasun Hospital, Hwasun, Korea.
Kyung-Hwa LeeDepartment of Pathology, Chonnam National University Hwasun Hospital, Hwasun, Korea.
Chae-Yong KimDepartment of Neurosurgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
In Ah KimDepartment of Radiation Oncology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Chang-Ki HongDepartment of Neurosurgery, Gangnam Severance Hospital, Yonsei University College of Health Science, Seoul, Korea.
Heon YooDepartment of Neuro-Oncology Clinic, Center for Specific Organs Cancer, National Cancer Center Hospital, National Cancer Center, Goyang, Korea.
Jin Hee KimDepartment of Radiation Oncology, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea.
Shin-Hyuk KangDepartment of Neurosurgery, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
Min Kyu KangDepartment of Radiation Oncology, Yeungnam University Medical Center, Yeungnam University College of Medicine, Daegu, Korea.
Eun-Young KimDepartment of Neurosurgery, Inha University Hospital, Inha University School of Medicine, Incheon, Korea.
Sun-Hwan KimDepartment of Neurosurgery, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, Korea.
Dong-Sup ChungDepartment of Neurosurgery, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea.
Sun-Chul HwangDepartment of Neurosurgery, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.
Joon-Ho SongDepartment of Neurosurgery, Hallym University Sacred Heart Hospital, Anyang, Korea.
Sung Jin ChoDepartment of Neurosurgery, Soonchunhyang University Hospital, Seoul, Korea.
Sun-Il LeeDepartment of Neurosurgery, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
Youn-Soo LeeDepartment of Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Kook-Jin AhnDepartment of Radiation, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Se Hoon KimDepartment of Pathology, Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul, Korea.
Do Hun LimDepartment of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ho-Shin GwakDepartment of Systemic Cancer Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Se-Hoon LeeDivision of Hematotology/Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Yong-Kil HongDepartment of Neurosurgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Yonsei University Health System · KRSeoul National University Bundang Hospital · KRThe Catholic University of Korea Seoul St. Mary's Hospital · KRChonnam National University Hwasun Hospital · KRInje University Haeundae Paik Hospital · KRNational Cancer Center · KRSamsung Medical Center · KRSeoul National University Hospital · KRUlsan College · KRYonsei University · KRBucheon University · KRChungnam National University Hospital · KRHallym University Sacred Heart Hospital · KRInha University Hospital · KRKeimyung University · KRKorea University Medical Center · KRKosin University Gospel Hospital · KRSoonchunhyang University Hospital Seoul · KRSungkyunkwan University · KRThe Catholic University of Korea Incheon St. Mary's Hospital · KR
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to investigate the feasibility and survival benefits of combined treatment with radiotherapy and adjuvant temozolomide (TMZ) in a Korean sample. MATERIALS AND
methodsA total of 750 Korean patients with histologically confirmed glioblastoma multiforme, who received concurrent chemoradiotherapy with TMZ (CCRT) and adjuvant TMZ from January 2006 until June 2011, were analyzed retrospectively.
resultsAfter the first operation, a gross total resection (GTR), subtotal resection (STR), partial resection (PR), biopsy alone were achieved in 388 (51.7%), 159 (21.2%), 96 (12.8%), and 107 (14.3%) patients, respectively. The methylation status of O
conclusionPatients treated with CCRT followed by adjuvant TMZ had more favorable survival rates and tolerable toxicity than those who did not undergo this treatment.
Indexed as
ChemoradiotherapyAdultAgedAged, 80 and overAntineoplastic Agents, AlkylatingBiopsyBrain NeoplasmsCombined Modality TherapyDacarbazineDisease ProgressionFemaleGlioblastomaHumansKaplan-Meier EstimateMagnetic Resonance ImagingMaleAntineoplastic Agents, AlkylatingDacarbazineTemozolomideChemoradiotherapyGlioblastomaMGMTTemozolomide
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.